Vaccine Target Articles & Analysis
41 news found
With advanced research equipment and an excellent expert team, the company can develop vaccines targeting different types of pathogens, including bacterial infections, fungal infections, viral infections, prion diseases, and parasitic infections. Utilizing system biology approaches, adjuvant, mRNA, and vector-based technologies, Protheragen provides mRNA ...
The development of vaccines against superbugs is an important area of research because vaccines can help prevent infections from occurring in the first place and reduce the need for antibiotics. ...
As disclosed earlier by the director, BOC Sciences' 2024 exhibition highlights include: Chemical Molecules: Peptides and Amino Acids, Nucleosides and Phosphoramidites, Inhibitors, Vaccine Adjuvants, Proteolysis Targeting Chimera (PROTAC), RNA Modulators, RNAi Products, Impurities, Carbohydrates, and Building Blocks. ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
Jake Kurtis, identified the parasite protein PfGARP as a target of human antibodies which kill up to 100% of parasites in vitro by inducing apoptosis or parasite programmed cell death – this discovery forms the basis of Ocean Biomedical’s lipid encapsulated mRNA-based vaccine and therapeutic monoclonal antibodies. Ocean’s breakthrough approach ...
Ocean Biomedical is accelerating development of a uniquely powerful malaria vaccine and several malaria therapeutics that target newly discovered pathways. ...
Approved Quotes “We are proud to work with Ziphius Vaccines in their early-stage program. The advancement of saRNA technologies is an exciting avenue for the development of vaccines and therapeutic programs, and we’re looking forward to a successful ...
” Chris Cardon, CEO of Ziphius Vaccines, said: “Efficient delivery of saRNA to the cells is a major limiting factor for the development and production of RNA based vaccines. ...
(Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. ...
ByVaxxinit
The AD Vaccine, YM7555, is a DNA Vaccine that targets both ABeta and TAU, which accumulate and are necessary for the development of AD. ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced that preclinical data from ZIP1642, its COVID-19 vaccine candidate, was published in the renowned scientific ...
Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other conditions such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). ...
ByVaxxinit
About Scancell Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications, development of a vaccine for COVID-19 and a growing portfolio of novel anti-TaG monoclonal antibodies. ImmunoBody® vaccines ...
ByScancell
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego. Dr. Keirstead is scheduled to deliver an opening ...
Oravax combines Oramed’s POD™ oral delivery technology with Premas’ proprietary virus like particle (VLP) triple antigen vaccine. The VLP vaccine targets three structural proteins potentially creating a more robust candidate for protection across emerging mutations of the coronavirus. The oral delivery should offer a more ...
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid ...
With the dramatic increase in positive cases of the Omicron variant, the global need for an oral vaccine that protects against current and future variants is crucial. An oral COVID-19 vaccine would significantly improve vaccination logistics and reduce costs. ...
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. ...
Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ‘Featured E-posters’ section (no. 97), as part of the conference. HPV research Current HPV vaccines are based on L1 proteins and protects against ...
IRVINE, Calif. – Nov. 16, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress. The Singapore-based congress is being held virtually November 17-18. Dr. Keirstead’s speaking details are as follows: Keynote: A Fully ...